Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APX 3330

Drug Profile

APX 3330

Alternative Names: APX3330; E-3330

Latest Information Update: 09 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Apexian Pharmaceuticals
  • Class Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Quinones; Small molecules
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Oxidoreductase modulators; Protein inhibitors; Transcription factor modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Age-related macular degeneration; Cancer; Haematological malignancies; Peripheral nervous system diseases
  • Discontinued Liver disorders

Most Recent Events

  • 26 Oct 2019 Interim efficacy, adverse events and pharmacodynamics data from a phase I trial in solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 (AACR-NCI-EORTC-2019)
  • 31 May 2019 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 12 Sep 2018 Pharmacodynamics data from preclinical trials in Cancer presented at 17th World Congress on Pain (WCP-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top